Dr. Yan Peng completed her Pediatric Residency/Chief Resident at Beijing Medical University Hospitals and practiced there as a Pediatric Nephrologist till 1993. After a combined six years of basic research on kidney disease at Mayo Clinic, Rochester, MN and UT-Southwestern Medical Center (UTSW), Dallas, TX, she went to University of Pittsburgh Medical Center (UPMC) for her Pathology Residency in 1999. Upon the completion, she took two one-year ACGME accredited fellowship trainings in Breast and Gynecologic Pathology at UPMC and Cytopathology at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, respectively. In 2005, she joined the Pathology Faculty at UTSW, where she has been practicing Surgical Pathology and Cytopathology till now. She is certified in Anatomic Pathology, Clinical Pathology, and Cytopathology by the American Board of Pathology.
Currently she is a Breast and Gynecologic Pathologist and a member of Cancer Committee at UTSW Simmons Cancer Center. As a co-investigator, she has participated in multiple National Cancer Institute (NCI) breast cancer and gynecologic cancer clinical trials.
Her specialties include Breast and Gynecologic Cancer Pathology, Cytopathology, Diagnostic Immunohistochemistry with a particular interest in unknown primary cancer work-up, and interpretation of prognostic and predictive tumor biomarkers tested by image analysis and fluorescence in-situ Hybridization (FISH).
- Medical School
- Beijing Medical University (1986)
- Beijing University Hospital (1989), Pediatrics
- Graduate School
- Beijing Medical University (1991)
- Mayo Clinic (1995), Physiology
- UT Southwestern Medical Center (1999), Molecular Nephrology Research
- University of Pittsburgh Medical Center (2003), Anatomic & Clinical Pathology
- University of Pittsburgh Medical Center Magee Womens Hospital (2004), Breast & Gynecologic Pathology
- Harvard Medical School/Beth Israel Deaconess Medical Center (2005), Cytopathology
- Comprehensive Immunohistochemical Markers including Prognostic Markers
- Evaluation of Breast Tissue for Diagnosis & Treatment Plans
- Biopsy & Cytology Correlation
- Cervical/Endocervical Biopsies & Endometrial Curetting
- HPV Hybridization for Cervical & Vulvar Biopsies
- Identification & Quantitation of Infectious Organisms
- Prognostic Markers for Endometrial Carcinomas
- Breast Cancer and Gynecologic Cancer Pathology
- Diagnostic, prognostic and predictive tumor biomarkers
- Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
- Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK Breast Cancer Res. Treat. 2015 Mar
- Quantification of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Using the Ventana Image Analysis System: Correlation With Gene Amplification by Fluorescence In Situ Hybridization: The Importance of Instrument Validation for Achieving High (>95%) Concordance Rate.
- Dennis J, Parsa R, Chau D, Koduru P, Peng Y, Fang Y, Sarode VR Am. J. Surg. Pathol. 2015 Jan
- Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma (TNBC): comparison with GATA3 expression and PELP1's potential role in TNBC
- Dang D, Raj G, Sarode V, Molberg K, Vadlamudi R and Peng Y* humpath. 2015 46 12 1829-1835
- KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer.
- Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, Peng Y, John GB, Li HC, Sadeghi N, Wright WE, Lum L, Corson TW, Shay JW Neoplasia 2014 Mar 16 3 247-256.e2
- Cutaneous and mammary apocrine carcinomas have different immunoprofiles.
- Piris A, Peng Y, Boussahmain C, Essary LR, Gudewicz TM, Hoang MP Hum. Pathol. 2014 Feb 45 2 320-6
- Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
- Cockburn A, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y, Rumnong Sarode V Hum. Pathol. 2014 Feb 45 2 249-58
- Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.
- Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA Oncogene 2014 Jan
- Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
- Sugianto J, Sarode V, Peng Y Hum. Pathol. 2013 Dec
- Roles of p53 and p16 in Triple-negative Breast Cancer (This article was selected to be featured on Oncology Central.)
- Dang D and Peng Y Breast Cancer Management (Future Medicine). 2013 2 6 537-544
- Decreased Androgen Receptor Expression is Associated with Distant Metastases in Patients with Androgen Receptor Expressing Triple-negative Breast Carcinoma.
- Sutton LM, Cao D, Sarode VR, Molberg KH, Torgbe K, Haley B and Peng Y. Am. J Clin. Pathol. 2012 138 511-516 (CME/SAM article)
Invasive Breast Carcinomas. In Peng Y, Kong C, and Chen Y. Practical Breast Pathology. Atkins K and Kong C (eds.), a volume in the Pattern Recognition Series. Kevin O. Leslie and Mark R.Wick (eds.).
Peng Y, Kong C, and Chen Y. (2013; 147-212). Philadelphia, PA, Elsevier
Honors & Awards
- President-Elect, International Association of Chinese Pathologists (IACP)
- President-Elect, The UTSW Faculty Senate
- Secretary, North Texas Society of Pathologists (NTSP)
- Distinguished Young Investigator Award in Medicine
Beijing, China (1993)
- Distinguished Scientist Award of Canada China Child Health Foundation
- Best National Medical Article Award
- Outstanding Medical Student Award and Scholarship
Beijing Medical University (1986)